Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performance.
To assess the potential positive inotropic properties of the drug MDL 17,043, 10 patients were studied who had impaired left ventricular (LV) performance and who were undergoing diagnostic cardiac catheterization (LV ejection fraction 16 to 46%). MDL 17,043 was given in repeated i.v. doses of 0.5 mg/kg every 15 minutes until a maximal effect was observed or a total dose of 3 mg/kg was attained. Cardiac output increased from 3.5 +/- 1.0 to 5.3 +/- 0.7 liters/min (p less than 0.005); pulmonary artery wedge pressure decreased from 22 +/- 4 to 9 +/- 5 mm Hg (p less than 0.001); and total systemic resistance decreased from 2,335 +/- 1,147 to 1,310 +/- 365 dyne cm-5 (p less than 0.025). Also, maximal LV dP/dt increased from 1,011 +/- 301 to 1,243 +/- 330 mm Hg/s (p less than 0.001). No significant changes in heart rate, systemic blood pressure, routine blood chemistries, complete blood counts or platelet counts were observed. Thus, MDL 17,043 has hemodynamic effects consistent with positive inotropic and vasodilating properties in patients with reduced LV performance. Because this agent is effective orally, further evaluation in patients with overt congestive heart failure is warranted.
D000328:Adult; D002316:Cardiotonic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017335:Enoximone; D006333:Heart Failure / Q000188:drug therapy*; D006352:Heart Ventricles / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects*; D013268:Stimulation, Chemical; D014664:Vasodilation / Q000187:drug effects*
D002316:Cardiotonic Agents; D007093:Imidazoles; D017335:Enoximone